Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes.
Francesco ZaccardiDavid E KloeckerJohn B BuseChantal MathieuKamlesh Khunti F MedSciMelanie J DaviesPublished in: Diabetes care (2020)